文献速递造血干细胞移植与细胞治疗血栓与止血

儿童移植相关血栓性微血管病的医疗资源利用及依库珠单抗治疗的意义

Pediatric transplant-associated thrombotic microangiopathy health care utilization and implications of eculizumab therapy.
PubMed 文献 · Blood Adv · 2024-01-01

该回顾性多中心研究纳入2015年1月1日至2019年7月1日接受造血细胞移植(HCT)的儿童,分析移植后第一年符合移植相关血栓性微血管病(TA-TMA)标准的住院费用。在同种异体移植中,调整严重3/4级急性移植物抗宿主病(GVHD)、感染和HLA错配后,TA-TMA组(n=137)与无TA-TMA组(n=238)费用无差异;在allo高危(HR)TA-TMA中,依库珠单抗治疗组(n=19)未调整费用显著高于支持治疗组(n=36),但调整胃肠道出血后依库珠单抗治疗与总费用增加无关。

要点

  • 同种异体移植中,调整严重GVHD、感染和HLA错配后,TA-TMA组与无TA-TMA组住院费用无差异。
  • allo高危TA-TMA中,依库珠单抗治疗组未调整费用显著高于支持治疗组。
  • 调整胃肠道出血后,依库珠单抗治疗与总费用增加无关。

核心结论

  • 在同种异体移植中,调整严重3/4级急性GVHD、感染和HLA错配后,TA-TMA组与无TA-TMA组费用无差异。
  • 在allo高危TA-TMA中,依库珠单抗治疗组未调整费用显著高于支持治疗组,但调整胃肠道出血后依库珠单抗治疗与总费用增加无关。
  • 需要更多研究来确定高危TA-TMA中医疗资源利用费用增加的病因,并预测更可能从依库珠单抗获益的患者,以减少医疗资源利用并改善结局。

研究设计与样本

  • 本研究为经机构审查委员会批准的回顾性多中心研究,纳入2015年1月1日至2019年7月1日接受HCT的连续儿童。
  • 从儿科健康信息系统数据中提取住院的标准化单位成本(按地理位置、生活成本差异和通货膨胀调整),并与临床数据链接。
  • 计算从干细胞输注前15天至HCT后1年的总费用和每日费用。

主要发现

  • 在同种异体移植受者中,调整严重3/4级急性GVHD、感染和HLA错配后,TA-TMA组(n=137)与无TA-TMA组(n=238)费用无差异。
  • 严重GVHD与费用增加显著相关。
  • 在allo高危TA-TMA中,依库珠单抗治疗组(n=19)未调整费用显著高于支持治疗组(n=36)。
  • 调整胃肠道出血后,依库珠单抗治疗与总费用增加无关;胃肠道出血在依库珠单抗组(n=6)与支持治疗组(n=0)中发生比例不均衡。

关键数值与推荐

  • 同种异体移植受者中,TA-TMA组n=137,无TA-TMA组n=238。
  • allo高危TA-TMA中,依库珠单抗治疗组n=19,支持治疗组n=36。
  • 胃肠道出血发生于依库珠单抗组n=6,支持治疗组n=0。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更多研究来确定高危TA-TMA中医疗资源利用费用增加的病因,并预测更可能从依库珠单抗获益的患者,以减少医疗资源利用并改善结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The health care use (HCU) burden of transplant-associated thrombotic microangiopathy (TA-TMA) and its treatments are unknown. The objective of this study was to investigate inpatient costs associated with meeting criteria for TA-TMA in the first year after hematopoietic cell transplant (HCT). This institutional review board-approved retrospective multicenter study included serial children who underwent HCT from 1 January 2015 to 1 July 2019. A standardized unit cost (adjusted for geographic location, differences in cost of living, and inflation) for inpatient hospitalization was extracted from the Pediatric Health Information System data and linked to clinical data. Both total cost and cost per day from 15 days before stem cell infusion to 1-year after HCT were calculated. Among allogeneic (allo) transplant recipients, after adjusting for severe grade 3/4 acute graft-versus-host disease (GVHD), infections, and HLA mismatch, costs were not different in TA-TMA (n = 137) vs no TA-TMA (n = 238). Severe GVHD was significantly associated with increased costs. Among allo high-risk (HR) TMA-TMA, unadjusted costs were significantly higher in the eculizumab-treated cohort (n = 19) than in the supportive care group (n = 36). However, after adjusting for gastrointestinal bleeding that occurred disproportionately in the eculizumab (n = 6) vs supportive care (n = 0) cohort, eculizumab treatment was not associated with increased total costs. More studies are needed to determine the etiology of increased HCU costs in those with HR-TA-TMA and predict those more likely to benefit from eculizumab, reducing HCU and improving outcomes.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Schoettler ML, Lehmann L, Kao PC, et al. Pediatric transplant-associated thrombotic microangiopathy health care utilization and implications of eculizumab therapy. Blood Adv. 2024. PMID: 38154068. doi:10.1182/bloodadvances.2023011078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。